DI-098 Consolidation of radipharmaceutical 99mtc-edda/hynic-toc in imaging tests for diagnosis of neuroendocrine tumours

BackgroundNeuroendocrine tumours (NET) overexpress somatostatin receptors on cell membranes. Imaging tests with somatostatin analogue tracers (SAT) are used for diagnosis and follow-up of NET and their metastases. Current guidelines recommend 111 In(DTPA)-octreotide for this use but new alternatives...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A157-A157
Main Authors: Estaún-Martínez, C, Moya-Carmona, I, Pedrosa-Ruiz, M, Dominguez-Rivas, Y, Valle, E Aguilar-Del, Fernández-Ovies, JM
Format: Article
Language:English
Subjects:
Aggregates
Biological products
Chromatography
Conflicts of interest
Neuroendocrine tumors
Nuclear medicine
Radiation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundNeuroendocrine tumours (NET) overexpress somatostatin receptors on cell membranes. Imaging tests with somatostatin analogue tracers (SAT) are used for diagnosis and follow-up of NET and their metastases. Current guidelines recommend 111 In(DTPA)-octreotide for this use but new alternatives are available, such as 99mTc-labelled SAT.PurposeTo study the consolidation of 99mTc-EDDA/HYNIC-TOC (99mTc-Tektrotyd) as SAT for the diagnose of NET in our centre.Material and methodsWe analysed the requests for 99mTc-Tektrotyd received from the nuclear medicine service from November 2015 to September 2016. This tracer was not commercialised in our country until September 2016, so it was necessary to justify its use to obtain National Medicines Agency approval. We created a database which included: age, diagnose and reasons to justify 99mTc-Tektrotyd use, instead of 111 In-labelled SAT in imaging tests. Data were retrieved from electronic health records, including clinical history and nuclear medicine service requests.Results32 requests were analysed: 28.125% of patients were
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.345